<DOC>
	<DOC>NCT02526875</DOC>
	<brief_summary>To Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine (Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy</brief_summary>
	<brief_title>Efficacy of a Telmisartan/S-Amlodipine on 24-hour BP Control in Hypertensive Patients Inadequately Controlled</brief_title>
	<detailed_description>A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine(Telminuvo®Tab. 40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1. More than 20 years in hypertension patient 2. Hypertension is satisfied with the Clinic blood pressure that was measured at the time of screening TreatmentNaive: Clinic Mean sitting diastolic blood pressure ≥ 100mmHg. TreatmentExperienced: Clinic Mean sitting diastolic blood pressure ≥ 90mmHg. 3. Hypertension is satisfied with the Clinic blood pressure that was measured at the time of randomization Clinic Mean sitting diastolic blood pressure ≥ 90mmHg 4. Patient who decided to participate and signed on an informed consent form willingly 1. Clinic Mean sitting systolic blood pressure ≥ 180mmHg or Clinic Mean sitting diastolic blood pressure ≥ 115mmHg at the time of Screening and Randomization 2. As night workers who sleep during the day and whose working hours including 00:00 to 04:00 3. Secondary Hypertension 4. Severe heart disease(Heart failure; New York Heart Association(NYHA) class 3, 4) and recent unstable angina or myocardial infarction or valvular heart disease or arrhythmia requiring treatment within the past 3 months 5. Severe cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage within 6 months 6. type 1 diabetes mellitus or Uncontrolled type 2 diabetes mellitus(HbA1c &gt; 8.0%) 7. Severe or malignant retinopathy 8. Abnormal laboratory test results Aspartate aminotransferase/Alanine aminotransferase &gt; Upper normal limit X 2 Serum creatinine &gt; Upper normal limit X 2 9. Acute of chronic inflammatory status requiring treatment 10. Need for other antihypertensive drugs during the trial 11. Need for prohibited medication specified in the protocol 12. A history of angioedema with ACE inhibitors or angiotensinⅡ receptor blockers 13. Severe hypersensitivity to amlodipine or telmisartan 14. History of drug or alcohol abuse within 6 months 15. Surgical or medical conditions History of major gastrointestinal surgery History of active inflammatory bowel syndrome within 12 months Abnormal pancreatic functions Gastrointestinal/rectal bleeding Urinary tract obstruction 16. Administration of other Investigational Product within 30 days 17. Pregnant, breastfeeding and childbearing age who don't use adequate contraception 18. History of malignant tumor within 5 years (including leukemia and lymphoma) 19. Another clinical condition in investigator's judgement</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>hypertension, Telmisartan/S-Amlodipine</keyword>
</DOC>